GlassScriptPhysician profile
Saira Babar
NPI 1306822317
$6,735.63
in general payments reported to CMS, 2019-2025
40 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $252 · 2021: $304 · 2022: $1,115 · 2023: $1,380 · 2024: $1,300 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,162.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,260.05 | 2019-2025 | |
| Abbvie INC. | $1,100.02 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $838.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $622.81 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $346.13 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $265.35 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $258.99 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.89 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $228.29 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $180.28 | 2019-2025 | Trintellix |
| Dexcom, INC. | $169.08 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $129.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $110.57 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $74.89 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $67.12 | 2025 | Voquezna |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.